Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6537
    +0.0014 (+0.22%)
     

  • OIL

    84.14
    +0.57 (+0.68%)
     

  • GOLD

    2,357.00
    +14.50 (+0.62%)
     

  • Bitcoin AUD

    98,356.13
    +812.63 (+0.83%)
     

  • CMC Crypto 200

    1,386.01
    -10.52 (-0.75%)
     

  • AUD/EUR

    0.6100
    +0.0027 (+0.44%)
     

  • AUD/NZD

    1.0987
    +0.0029 (+0.27%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,118.29
    +39.43 (+0.49%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,051.92
    +134.64 (+0.75%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Optinose to Present at the Needham Virtual Healthcare Conference

Optinose, Inc.
Updated ·1-min read
Optinose, Inc.
Optinose, Inc.

YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023 at 3:45 p.m. ET.

To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

A replay of the webcast will be available for 30 days following the conclusion of the event.

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531